Immune monitoring in SIRS and sepsis based on the PIRO model;Immunmonitoring bei SIRS und sepsis auf Grundlage des PIRO-modells

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 45, 2008, Pages 2332-2336

  Meisel, Christian ^a   Hoflich C ^a   Volk, H D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anti inflammatory; Immune monitoring; Immunoparalysis; PIRO model; Pro inflammatory; Sepsis; Systemic inflammatory response syndrom (SIRS)

Indexed keywords

C REACTIVE PROTEIN; ENDOTOXIN; HLA DR ANTIGEN; INTERLEUKIN 18; INTERLEUKIN 6; MANNOSE BINDING LECTIN; PROCALCITONIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; DISEASE PREDISPOSITION; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGICAL MONITORING; IMMUNOPATHOGENESIS; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BIOLOGICAL MODEL; DIFFERENTIAL DIAGNOSIS; IMMUNE SYSTEM; IMMUNOLOGY; PATHOPHYSIOLOGY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 55249123457     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1100924     Document Type: Review

References (30)

1. ACCP/SCCM. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 31: 864-74
2. Becker KL, Snider R et al. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941-52
3. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006; 67: 247-56
4. Brunkhorst F. Definition und Diagnose der Sepsis nach aktuellen Kriterien. Klinikarzt 2004; 33: 167-172
5. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-91
6. Docke WD, Hoflich C et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005; 51: 2341-7
7. Döcke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-81
8. Gerlach H. Von Roger Bone to PIRO. Anasthesiol Intensivmed Notfallmed Schmerzther 2006; 41: 32-4
9. Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004; 2: 181-7
10. Harms H, Prass K, Meisel C et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS ONE 2008; 14: e2158-
11. Jensen JU, Lundgren B, Lundgren JD. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007; 7: 499-500
12. Kox WJ, Volk T et al. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26: S124-8
13. Lam HS, Ng PC. Biochemical markers of neonatal sepsis. Pathology 2008; 40: 141-8
14. Levy MM, Fink MP et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6
15. Lode H, Harnoss CM. Infection from the viewpoint of the infectiologist. Beitr Infusionsther Klin Ernahr 1983; 10: 17-24
16. Monneret G, Venet F et al. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008; 14: 64-78
17. Moreno RP, Metnitz B, Adler L et al. Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med 2008; 34: 496-504
18. Müller B, Christ-Crain M, Schuetz P. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007; 7: 498-9
19. Nierhaus A, Montag B, Timmler N et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29: 646-51
20. Reinhart K, Brunkhorst FM. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007; 7: 500-2
21. Reinhart K, Meisner M et al. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006; 22: 503-19, ix-x
22. Reinsberg J, Dembinski J et al. Determination of total interleukin-8 in whole blood after cell lysis. Clin Chem 2000; 46: 1387-94
23. Strohmeyer JC, Blume C, Meisel C et al. Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients. Cytometry B Clin Cytom 2003; 53: 54-62
24. Sunden-Cullberg J, Norrby-Teglund A et al. The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis 2006; 19: 231-6
25. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 210-7
26. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem Soc Trans 2003; 31: 768-9
27. Volk HD, Reinke P et al. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 2000; 74: 162-77
28. Volk HD, Thieme M et al. Alterations in function and phenotype of monocytes from patients with septic disease - predictive value and new therapeutic strategies. Behring Inst Mitt 1991; 88: 208-15
29. Winning J, Claus RA et al. Molecular biology on the ICU. From understanding to treating sepsis. Minerva Anestesiol 2006; 72: 255-67
30. Yan SF, Ogawa S et al. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int 1997; 51: 41-25